免疫風濕病人之生物製劑治療及護理

Biologics Therapy and Nursing for Patients with Autoimmune and Rheumatic Diseases

10.6142/VGHN.31.2.137

曹彥博(Yen-Po Tsao)；王佳雯(Chia-Wen Wang)

免疫風濕疾病 ； 生物製劑 ； 護理 ； autoimmune ； rheumatism disease ； biologic ； nursing

榮總護理

31卷2期（2014 / 06 / 01）

137 - 143

繁體中文

生物製劑可有效抑制發炎機轉，常用以控制免疫風濕病人的症狀及病程變化。常見的皮下注射藥物為甲型腫瘤壞死因子拮抗劑，而採用靜脈注射的生物製劑有第6介白質接受器抗體、T細胞協同刺激調節劑及B細胞標靶藥物。生物製劑普遍易造成B型肝炎病毒再活化、感染與惡性腫瘤。故應審慎評估並持續追蹤，落實預防感染措施，有效的監控副作用，使生物製劑發揮最大療效，謀求病人之最大福祉。

The development of biologics indicates substantial progress for treating autoimmune and rheumatic diseases. Subcutaneous TNF-α blockers are frequently used in Taiwan. Intravenous biologics include IL-6 receptor blockers, T-cell costimulatory modulators, and B cell target therapy. Overall, biologics entail numerous challenges, such as infection events, HBV reactivation, and the possibility of increasing risk for cancer development. Continual monitoring and infection prevention are crucial among patients who use biologics to maximize drug effects.